Heather McArthur

12PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEconomic models and forecastingPredictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Apr 16, 2026
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer.

|Jan 16, 2026
GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast Cancer.

Bethania Santos, Maycon Marção, Ishrat Durdana

|Dec 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy.

Barbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro

|Nov 14, 2025
Real-World Outcomes of Elacestrant in ER+, HER2-, ESR1-Mutant Metastatic Breast Cancer.

Hope S Rugo, Virginia Kaklamani, Heather McArthur

|Feb 07, 2025
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.

Heather L McArthur, Sara M Tolaney, Rebecca Dent

|Jan 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Sherene Loi, Roberto Salgado, Giuseppe Curigliano

Pageof 2

Frequent Collaborators

2 joint publications

Nadia Harbeck

2 joint publications

Peter Schmid

2 joint publications

David B Page

1 joint publications

Jasmine Plummer